GR3006073T3 - - Google Patents

Info

Publication number
GR3006073T3
GR3006073T3 GR920402402T GR920402402T GR3006073T3 GR 3006073 T3 GR3006073 T3 GR 3006073T3 GR 920402402 T GR920402402 T GR 920402402T GR 920402402 T GR920402402 T GR 920402402T GR 3006073 T3 GR3006073 T3 GR 3006073T3
Authority
GR
Greece
Prior art keywords
molecules
icam
asthma
bind
treatment
Prior art date
Application number
GR920402402T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3006073T3 publication Critical patent/GR3006073T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR920402402T 1989-03-09 1992-10-26 GR3006073T3 (enExample)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32101889A 1989-03-09 1989-03-09
US32123989A 1989-03-09 1989-03-09
US32123789A 1989-03-09 1989-03-09
US32448189A 1989-03-16 1989-03-16
US40140989A 1989-09-01 1989-09-01

Publications (1)

Publication Number Publication Date
GR3006073T3 true GR3006073T3 (enExample) 1993-06-21

Family

ID=27541038

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920402402T GR3006073T3 (enExample) 1989-03-09 1992-10-26

Country Status (13)

Country Link
EP (1) EP0387701B1 (enExample)
JP (1) JP3119483B2 (enExample)
KR (1) KR0177519B1 (enExample)
AT (1) ATE79270T1 (enExample)
AU (1) AU638450B2 (enExample)
CA (1) CA2047721C (enExample)
DE (1) DE69000248T2 (enExample)
DK (1) DK0387701T3 (enExample)
ES (1) ES2035668T3 (enExample)
GR (1) GR3006073T3 (enExample)
HU (1) HU216313B (enExample)
NZ (1) NZ232868A (enExample)
WO (1) WO1990010453A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (en) 1988-09-01 1999-11-10 Bayer Corporation A human rhinovirus receptor protein that inhibits virus infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US5776775A (en) * 1989-02-21 1998-07-07 Dana-Farber Cancer Institute Anti-LAM 1-3 antibody and hybridoma
ATE184049T1 (de) * 1990-07-20 1999-09-15 Bayer Ag Multimere formen des menschlichen rhinovirus- rezeptorproteins
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
AU8765391A (en) * 1990-10-03 1992-04-28 Boehringer Ingelheim Pharmaceuticals, Inc. Method for treating inflammation using anti-idiotypic antibodies
CA2056143A1 (en) * 1990-11-28 1992-05-29 Michael S. Diamond The mac-1 binding site of icam-1
ATE145827T1 (de) * 1991-04-03 1996-12-15 Boehringer Ingelheim Pharma Verfahren zur hemmung der sauerstofftoxizität in den lungen
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
EP0551501B1 (en) * 1991-07-31 1998-11-18 Boehringer Ingelheim Pharmaceuticals Inc. Use of endothelial-leukocyte adhesion molecule-1 and antibodies thereto in the treatment of asthma
EP0610298A1 (en) * 1991-10-01 1994-08-17 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5708141A (en) * 1992-05-11 1998-01-13 Corvas International, Inc. Neutrophil inhibitors
CA2116109A1 (en) * 1992-06-22 1994-01-06 Jeffrey M. Greve Multimeric forms of human rhinovirus receptor protein
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128727T1 (de) * 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
ATE114972T1 (de) * 1987-11-02 1994-12-15 Baylor College Medicine Verwendung von icam-1 oder ihre funktionelle derivate zur behandlung unspezifischer entzündungen.
CA1341055C (en) * 1987-12-08 2000-07-18 Alan Mcclelland Transfectant cell lines which express the major human rhinovirus receptor

Also Published As

Publication number Publication date
CA2047721C (en) 2004-01-06
HUT65843A (en) 1994-07-28
ES2035668T3 (es) 1993-04-16
DK0387701T3 (da) 1992-12-07
EP0387701A1 (en) 1990-09-19
KR920700667A (ko) 1992-08-10
WO1990010453A1 (en) 1990-09-20
ATE79270T1 (de) 1992-08-15
JP3119483B2 (ja) 2000-12-18
HU902883D0 (en) 1991-12-30
CA2047721A1 (en) 1990-09-10
KR0177519B1 (ko) 1999-03-20
DE69000248D1 (de) 1992-09-17
JPH04504127A (ja) 1992-07-23
DE69000248T2 (de) 1993-01-07
NZ232868A (en) 1995-05-26
HU216313B (hu) 1999-06-28
AU5349990A (en) 1990-10-09
EP0387701B1 (en) 1992-08-12
AU638450B2 (en) 1993-07-01

Similar Documents

Publication Publication Date Title
HUT65843A (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
AU582762B2 (en) Fibrous absorption body for use in disposable articles and method for the production thereof
AU648016B2 (en) Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in antiviral therapy
EP0488061A3 (en) The mac-1 binding site of icam-1
ES2052871T3 (es) Preparacion de bis (3,5-di-t-butil-4-hidroxifeniltio)metano.
ATE73045T1 (de) Verfahren zur herstellung von holzspanplatten u.dgl. und entsprechende doppelbandpressen.
DE69813839D1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
IL88080A0 (en) Substituted tetralins,chromans and related compounds in the treatment of asthma,arthritis and related diseases
DE3876688D1 (de) Thixothrope anstrichmittelzusammensetzung und gegenstaende damit.
IL86299A (en) Manganese (ii) chelates of n, n) -dipyridoxyldiamine- n-acetic (or n,n)-diacetic)- acid derivatives and their use as nmri contrast agents
EP0730449A4 (en) NOVEL PALLADIUM COMPLEXES AND METHODS OF USE THEREOF IN THE TREATMENT OF TUMORS AND PSORIASIS
ATE112568T1 (de) Verfahren zur herstellung von 9-substituierten guaninderivaten und zwischenprodukte zur verwendung im verfahren.
EP0318233A3 (en) Improvements in or relating to serotonin and norepinephrine uptake inhibitors
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
ZA901842B (en) Use of intercellular adhesion molecules,and their binding ligans in the treatment of asthma
AU2763692A (en) Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
NZ226569A (en) Process for the two-stage inactivation of viruses using both heat and alkalisation
ZA893310B (en) Novel strobilurine derivatives,their preparation and their use
GB9008215D0 (en) Improvements in or relating to the treatment of surfaces
EP0685492A3 (de) Verfahren zur Herstellung molekulareinheitlicher hyperpolymerer Hämoglobine.
EP0431953A3 (en) Pyrrolopyrimidine derivatives, their production and use
AU2421788A (en) Improvements in or relating to effluent treatment
FI923546A7 (fi) Tetraliini- ja kromaanijohdannaisia, jotka ovat käyttökelpoisia astman ,niveltulehduksen ja vastaavien sairauksien hoidossa
EP0310260A3 (en) Platinum complexes and their use as anti-tumor agents